Takeda Wants Orexigen To Bear $200 Million Contrave CV Trial Cost
This article was originally published in The Pink Sheet Daily
Takeda initiated dispute resolution proceedings against Orexigen demanding the smaller company pay the full cost of a new cardiovascular outcomes trial after Orexigen’s controversial data disclosure from the initial Light study.
You may also be interested in...
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.
The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.